KR20020004987A - 유전자 전달을 위한 바이러스 엔벨로프 벡터 - Google Patents
유전자 전달을 위한 바이러스 엔벨로프 벡터 Download PDFInfo
- Publication number
- KR20020004987A KR20020004987A KR1020017012501A KR20017012501A KR20020004987A KR 20020004987 A KR20020004987 A KR 20020004987A KR 1020017012501 A KR1020017012501 A KR 1020017012501A KR 20017012501 A KR20017012501 A KR 20017012501A KR 20020004987 A KR20020004987 A KR 20020004987A
- Authority
- KR
- South Korea
- Prior art keywords
- gene
- gene transfer
- virus
- hvj
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16663—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18823—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18861—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18861—Methods of inactivation or attenuation
- C12N2760/18863—Methods of inactivation or attenuation by chemical treatment
Abstract
Description
Claims (19)
- 바이러스 엔벨로프를 포함하는 유전자 전달 벡터
- 제 1항에 있어서, 상기 바이러스는 야생형 또는 재조합형 바이러스로부터 유래된 것임을 특징으로 하는 유전자 전달 벡터
- 제 1항 또는 제 2항에 있어서, 상기 바이러스는 레트로비리데, 토카비리데, 코로나비리데, 플라비비리데, 파라믹소비리데, 오르소믹소비리데, 부니아비리데, 랍도비리데, 폭스비리데, 헤르페스비리데, 바큘로비리데 및 헤파드나비리데 등으로 구성된 군에서 선택된 일개과에 속함을 특징으로 하는 유전자 전달 벡터
- 제 3항에 있어서, 상기 바이러스는 HVJ임을 특징으로 하는 유전자 전달 벡터
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 유전자 전달 벡터는 외인성 유전자를 포함하는 바이러스를 혼합하는 단계와 혼합물을 두 번이상 얼리고 녹이는단계를 포함함을 특징으로 하는 유전자 전달 벡터
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 벡터는 세정제 존재 하에서 외인성 유전자를 지닌 바이러스를 혼합하는 단계를 포함하는 방법에 의해 제조함을 특징으로 하는 유전자 전달 벡터
- 제 5항 또는 제 6항에 있어서, 바이러스를 불활성화 시키는 단계를 더욱 포함함을 특징으로 하는 유전자 전달 벡터
- 제 7항에 있어서, 상기 세정제는 옥틸글루코사이드, 트리톤 X-100, CHAPS 및 NP-40으로 이루어진 군에서 선택된 것임을 특징으로 하는 유전자 전달 벡터
- 제 8항에 있어서, 상기 세정제는 옥틸글루코사이드임을 특징으로 하는 유전자 전달 벡터
- 제 1항 내지 제 9항 중 어느 한 항에 있어서, 황산 프로타민을 외인성 유전자에 첨가하는 단계를 더욱 포함하는 방법임을 특징으로 하는 유전자 전달 벡터
- 제 1항 내지 제 10항 중 어느 한 항에 있어서, 유전자 도입은 동물에 생체내 조직에 행함을 특징으로 하는 유전자 전달 벡터
- 제 11항에 있어서, 상기 조직은 간, 골격근육, 자궁, 뇌, 눈, 경동맥, 피부, 혈관, 폐, 심장, 신장, 비장, 암조직, 신경, B 림파구, 호홉관 조직으로 이루어진 군에서 선택된 조직임을 특징으로 하는 유전자 전달 벡터
- 제 1항 내지 제 12항의 유전자 전달 벡터를 포함하는 유전자 치료용 의학 조성물
- 제 1항 내지 제 12항의 유전자 전달 벡터를 포함하는 유전자 라이브러리 스크리닝 키트
- 외인성 유전자를 포함하는 바이러스를 혼합하는 단계와 혼합물을 두 번이상 얼리고 녹이는 단계를 포함함을 특징으로 하는 유전자 전달용 바이러스 엔벨로프 벡터를 지니는 유전자 전달 벡터를 제조하는 방법
- 상기 방법은 세정제 존재 하에서 외인성 유전자를 지닌 바이러스를 혼합하는 단계를 포함하는 방법임을 특징으로 하는 유전자 전달용 바이러스 엔벨로프 벡터를 지니는 유전자 전달 벡터의 제조방법
- 제 15 항 또는 제 16항에 있어서, 바이러스를 불활성화시키는 단계를 더욱 포함함을 특징으로 하는 유전자 전달 벡터의 제조방법
- 원하는 외인성 유전자를 지닌 제 1항 내지 제 12항의 유전자 전달 벡터를 제조하는 단계, 유전자를 유전자 전달 벡터를 통하여 분리된 동물 조직에 도입하는 단계를 포함하는 유전자를 분리된 동물 조직에 도입하는 방법
- 부유세포를 황산 프로타민 존재 하에서 제 1항 내지 제 12항 중 어느 한 항에 따라 제조된 유전자 전달 벡터와 혼합하고, 혼합물을 원심분리시키는 단계를 포함하는 외인성 유전자를 부유세포(suspended cell)에 도입시키는 방법
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2000-00025596 | 2000-02-02 | ||
JP2000025596 | 2000-02-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077009410A Division KR100847385B1 (ko) | 2000-02-02 | 2001-02-02 | 유전자 전달을 위한 바이러스 엔벨로프 벡터 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020004987A true KR20020004987A (ko) | 2002-01-16 |
KR100776475B1 KR100776475B1 (ko) | 2007-11-16 |
Family
ID=18551433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077009410A KR100847385B1 (ko) | 2000-02-02 | 2001-02-02 | 유전자 전달을 위한 바이러스 엔벨로프 벡터 |
KR1020017012501A KR100776475B1 (ko) | 2000-02-02 | 2001-02-02 | 유전자 전달을 위한 바이러스 엔벨로프 벡터 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077009410A KR100847385B1 (ko) | 2000-02-02 | 2001-02-02 | 유전자 전달을 위한 바이러스 엔벨로프 벡터 |
Country Status (10)
Country | Link |
---|---|
US (3) | US6913923B2 (ko) |
EP (1) | EP1170363B1 (ko) |
KR (2) | KR100847385B1 (ko) |
CN (3) | CN100532559C (ko) |
AU (1) | AU769385C (ko) |
CA (1) | CA2369491C (ko) |
DE (1) | DE60131498T8 (ko) |
HK (1) | HK1047449A1 (ko) |
TW (1) | TWI303663B (ko) |
WO (1) | WO2001057204A1 (ko) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2369491C (en) * | 2000-02-02 | 2008-09-02 | Yasufumi Kaneda | Virus envelope vector for gene transfer |
CN1281276C (zh) * | 2000-06-27 | 2006-10-25 | 株式会社载体研究所 | 用于将基因引入肾细胞的病毒载体 |
ATE390938T1 (de) * | 2001-02-20 | 2008-04-15 | Anges Mg Inc | Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis |
US20040253272A1 (en) * | 2001-08-02 | 2004-12-16 | Yasufumi Kaneda | Process for producing inactivated virus envelopes |
EP1447451A4 (en) * | 2001-09-28 | 2006-06-07 | Dnavec Research Inc | MAMMALIAN INFECTIVE, EPITOPEED BETA2m CODING VIRUS VECTOR AND ITS USE |
ATE421889T1 (de) | 2002-02-01 | 2009-02-15 | Anges Mg Inc | Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen |
JPWO2003103721A1 (ja) * | 2002-06-06 | 2005-10-06 | アンジェスMg株式会社 | 脳血管障害遺伝子治療剤 |
JPWO2004035779A1 (ja) | 2002-08-27 | 2006-02-16 | アンジェスMg株式会社 | ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム |
EP1559780A1 (en) * | 2002-10-01 | 2005-08-03 | Dnavec Research Inc. | Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity |
CA2501701A1 (en) * | 2002-11-01 | 2004-05-13 | Genomidea Inc. | Chemotherapeutic agent-incorporated pharmaceutical preparation |
US20060099597A1 (en) * | 2002-11-21 | 2006-05-11 | Yasufumi Kaneda | Method of isolating nucleic acid having desired functional property and kit therefor |
JP2004289816A (ja) * | 2003-03-06 | 2004-10-14 | Matsushita Electric Ind Co Ltd | 遠隔制御装置、遠隔制御方法および被遠隔制御装置 |
WO2005094878A1 (ja) | 2004-03-31 | 2005-10-13 | Genomidea Inc. | 抗腫瘍作用を有する組成物 |
CA2562904C (en) | 2004-04-27 | 2013-07-02 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
ES2357772T3 (es) * | 2004-06-14 | 2011-04-29 | Ishihara Sangyo Kaisha, Ltd. | Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana. |
JP5190958B2 (ja) * | 2005-07-14 | 2013-04-24 | ウェルスタット バイオロジクス コーポレイション | ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置 |
US20090214496A1 (en) * | 2006-01-30 | 2009-08-27 | Licentia Ltd. | Bmx/etk tyrosine kinase gene therapy materials and methods |
JP5102635B2 (ja) * | 2006-01-31 | 2012-12-19 | 石原産業株式会社 | エンベロープウイルスの構成成分に親和性を有するポリペプチドと細胞内物質導入への使用 |
JP2008308440A (ja) * | 2007-06-14 | 2008-12-25 | Genomidea Inc | 癌治療用薬剤送達ビヒクルおよびその製造方法ならびにそれを用いた製剤 |
EP2345415B1 (en) * | 2008-09-16 | 2015-01-21 | GenomIdea Inc. | Therapeutic/prophylactic agent for prostate cancer |
WO2010041716A1 (ja) | 2008-10-10 | 2010-04-15 | クリングルファーマ株式会社 | 腱骨移行部組織または靭帯骨移行部組織の再生促進剤 |
EP3252068A3 (en) | 2009-10-12 | 2018-03-14 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
JP4653242B1 (ja) | 2010-02-12 | 2011-03-16 | ナノキャリア株式会社 | 粒子状医薬組成物 |
CN102858961A (zh) * | 2010-05-03 | 2013-01-02 | 葛兰素史密丝克莱恩生物有限公司 | 新方法 |
CN103941924B (zh) * | 2014-04-25 | 2016-09-14 | 锐达互动科技股份有限公司 | 一种实现红外光编解码的互动投影方法 |
EP3536329B1 (en) | 2016-11-01 | 2022-08-31 | Osaka University | Anticancer agent comprising hvj-e and a neutralizing antibody against pd-1 |
CN109963506B (zh) * | 2016-11-22 | 2024-05-07 | 西达-赛奈医疗中心 | 一种新型的转染和药物递送装置 |
CN110072537B (zh) | 2016-12-06 | 2023-03-14 | 国立大学法人大阪大学 | 朊病毒样蛋白病用治疗药 |
WO2022059703A1 (ja) | 2020-09-16 | 2022-03-24 | 国立大学法人大阪大学 | がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005476B1 (de) | 1978-05-17 | 1981-12-30 | Dr. Karl Thomae GmbH | Verfahren zur Herstellung von Humaninterferon |
CA1282721C (en) * | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
ATE132034T1 (de) * | 1990-10-19 | 1996-01-15 | Univ Florida | Künstliche virushüllen |
US5879685A (en) * | 1991-05-08 | 1999-03-09 | Schweiz, Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5244635A (en) | 1992-06-19 | 1993-09-14 | Cirrus Diagnostics, Inc. | Centrifuge vessel with coaxial waste chamber having cap to prevent waste fluid transfer from the chamber into the vessel |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
FR2713657B1 (fr) * | 1993-12-13 | 1996-03-01 | Transgene Sa | Nouveaux vecteurs pour le traitement du sida. |
US5843459A (en) * | 1996-01-19 | 1998-12-01 | Human Gene Therapy Research Institute | Differential inactivation of nucleic acids by chemical modification |
JP3744583B2 (ja) * | 1996-03-01 | 2006-02-15 | 株式会社ディナベック研究所 | 遺伝子導入用組成物及び該組成物を用いた遺伝子導入方法 |
US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US5683866A (en) * | 1996-05-09 | 1997-11-04 | Sarkar; Debi P. | Process for producing a targeted gene |
US6183752B1 (en) * | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6051428A (en) * | 1997-03-21 | 2000-04-18 | Sloan-Kettering Institute For Cancer Research | Rapid production of autologous tumor vaccines |
US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
US6472375B1 (en) * | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
US6372957B1 (en) * | 1998-11-10 | 2002-04-16 | Board Of Regents, The University Of Texas System | Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use |
CA2369491C (en) | 2000-02-02 | 2008-09-02 | Yasufumi Kaneda | Virus envelope vector for gene transfer |
US6509162B1 (en) * | 2000-02-29 | 2003-01-21 | Yale University | Methods for selectively modulating survivin apoptosis pathways |
-
2001
- 2001-02-02 CA CA002369491A patent/CA2369491C/en not_active Expired - Lifetime
- 2001-02-02 DE DE60131498T patent/DE60131498T8/de active Active
- 2001-02-02 US US09/937,839 patent/US6913923B2/en not_active Expired - Lifetime
- 2001-02-02 TW TW090102208A patent/TWI303663B/zh not_active IP Right Cessation
- 2001-02-02 KR KR1020077009410A patent/KR100847385B1/ko active IP Right Grant
- 2001-02-02 CN CNB018005675A patent/CN100532559C/zh not_active Expired - Lifetime
- 2001-02-02 AU AU30578/01A patent/AU769385C/en not_active Expired
- 2001-02-02 WO PCT/JP2001/000782 patent/WO2001057204A1/ja active IP Right Grant
- 2001-02-02 CN CNB2004101002195A patent/CN100542614C/zh not_active Expired - Lifetime
- 2001-02-02 KR KR1020017012501A patent/KR100776475B1/ko active IP Right Grant
- 2001-02-02 CN CNA2008100016273A patent/CN101302536A/zh active Pending
- 2001-02-02 EP EP01902759A patent/EP1170363B1/en not_active Expired - Lifetime
-
2002
- 2002-11-27 HK HK02108562.9A patent/HK1047449A1/zh unknown
-
2004
- 2004-04-14 US US10/824,757 patent/US7279333B2/en not_active Expired - Lifetime
-
2005
- 2005-05-10 US US11/126,770 patent/US7803621B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU769385C (en) | 2004-07-29 |
CN100532559C (zh) | 2009-08-26 |
DE60131498T2 (de) | 2008-10-02 |
CN1365388A (zh) | 2002-08-21 |
HK1047449A1 (zh) | 2003-02-21 |
DE60131498D1 (de) | 2008-01-03 |
CA2369491A1 (en) | 2001-08-09 |
CA2369491C (en) | 2008-09-02 |
KR20070059182A (ko) | 2007-06-11 |
US7279333B2 (en) | 2007-10-09 |
US20040219674A1 (en) | 2004-11-04 |
WO2001057204A1 (fr) | 2001-08-09 |
KR100847385B1 (ko) | 2008-07-18 |
KR100776475B1 (ko) | 2007-11-16 |
AU3057801A (en) | 2001-08-14 |
EP1170363B1 (en) | 2007-11-21 |
US7803621B2 (en) | 2010-09-28 |
TWI303663B (en) | 2008-12-01 |
US6913923B2 (en) | 2005-07-05 |
CN1657103A (zh) | 2005-08-24 |
US20030013195A1 (en) | 2003-01-16 |
CN101302536A (zh) | 2008-11-12 |
CN100542614C (zh) | 2009-09-23 |
EP1170363A4 (en) | 2002-06-12 |
AU769385B2 (en) | 2004-01-22 |
US20050239188A1 (en) | 2005-10-27 |
EP1170363A1 (en) | 2002-01-09 |
DE60131498T8 (de) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100776475B1 (ko) | 유전자 전달을 위한 바이러스 엔벨로프 벡터 | |
JP3942362B2 (ja) | 遺伝子導入のためのウイルスエンベロープベクター | |
Strauss Jr et al. | Identification of the membrane protein and" core" protein of Sindbis virus. | |
ES2295175T3 (es) | Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas. | |
US20050032044A1 (en) | Composition for viral preservation | |
CA2584815C (en) | Stable and filterable enveloped virus formulations | |
Shoji et al. | Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells | |
KR20210120013A (ko) | 핵산 전달 복합체 | |
JP4219957B2 (ja) | 遺伝子導入のためのウイルスエンベロープベクター | |
JP2002065278A (ja) | Hvjの融合タンパク質を含有する遺伝子移入ビヒクル | |
ES2280254T3 (es) | Vector de virus sendai recombinante para introducir genes exogenos en el epitelio de las vias respiratorias. | |
JP3744583B2 (ja) | 遺伝子導入用組成物及び該組成物を用いた遺伝子導入方法 | |
ES2215073T3 (es) | Virosomas de dosper cationicos. | |
JP4848142B2 (ja) | 膜融合活性のある不活性化ウイルスエンベロープの凍結乾燥組成物 | |
KR20010072359A (ko) | 접촉 침윤력을 갖는 rna바이러스 벡터 | |
JP4497894B2 (ja) | 物質導入剤およびその製造方法 | |
EP0859846A1 (en) | Rabies recombinant adenovirus | |
Kaneda et al. | Progress in Gene Therapy: Basic and Clinical Frontiers, pp. 225-243 R. Bertolotti et al.(Eds)© VSP 2000 | |
JPWO2005090585A1 (ja) | ウイルスベクターによる固相遺伝子導入方法、その方法のための組成物、およびその方法のための装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20121023 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131022 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141021 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161019 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171018 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181018 Year of fee payment: 12 |